Determination Of Stavudine Research Articles

Разработка и валидация методики изолирования ставудина из биологических жидкостей

Objective - study of isolating Stavudine from biological fluids (urine, blood plasma). Materials and methods. Objects of research: substance and tablets of 30 mg Stavudine. Reagents: purified water, chloroform, ethyl acetate, dichloromethane, ether, heptane, toluene, acetone, 95% ethyl alcohol, 0.1 M hydrochloric acid solution, 10% ammonium hydroxide solution, 5%solutions of sodium sulfate, 20%sodium sulfate saturated, sodium chloride, sodium chloride saturated, 20%ammonium sulfate, ammonium sulfate saturated. Universal ionomer IT-1101. Stavudine was isolated by liquid-liquid extraction. To detect and quantify Stavudine, thin - layer sorbent chromatography (TLC) and UV spectrophotometry were used. Statistical data processing was performed using the software package for Windows XP (Microsoft Excel), and using the Student's t-test. Results. When using thin-layer chromatography to identify Stavudine, it was found that the Rf value of the spots of Stavudine extracts from biological material corresponded to the Rf value range of 0.67-0.69. The Rf spot value of the standard Stavudine witness sample corresponded to (0.68±0.01). The stability study showed that the Stavudine solution is stable in a hydrochloric acid solution of 0.1 M, in which the absorption spectrum of Stavudine is characterized by absorption maxima at wavelengths of 209±1 and 267±1 nm. The wavelength of 267±1 nm was chosen as the analytical wavelength for the quantitative determination of Stavudine. In the course of the study, various factors affecting the degree of extraction of Stavudine from aqueous solutions were studied. The extractant is ethyl acetate, pH 3, the electrolyte is a saturated solution of ammonium sulfate. The extraction time is 7 minutes, twice. Conclusion. Methods of identification and quantitative determination of Stavudine in extracts from urine and blood plasma by TLC and UV spectrophotometry have been developed. Methods of isolation of Stavudine from urine and blood plasma using the liquid-liquid extraction method have been developed (93.33±2.02%; 89.77±2.02% respectively).

Liquid Chromatography-Tandem Mass Spectrometric Assay for Determination of Stavudine in Human Plasma

A LC-MS/MS method for determination of stavudine in human plasma was established and validated, and it was applied to the pharmaceutical formulations bioequivalence study. 0.5 mL plasma sample was extracted by liquid-liquid extraction. Stavudine was detected by a LC-MS/MS system. The pharmacokinetic parameters of stavudine in different formulations were calculated by noncompartment model statistics. The method was linear over the concentration ranges 5.00–1000 ng/mL in plasma. The intra- and interassay relative standard deviation (RSD) was <10%. The average accuracies for the assay at three concentrations (5.00, 80.0, and 900 ng/mL) were from 100.2% to 102.5%. Pharmacokinetic parameters of stavudine reference formulation were obtained as follows:Tmaxwas0.6±0.2 h,Cmaxwas480.7±150.9 g/L,t1/2was1.7±0.4 h, andAUC0-twas872.8±227.8 g·h/L, and pharmacokinetic parameters of stavudine test formulation were obtained as follows:Tmaxwas0.5±0.2 h,Cmaxwas537.5±178.5 g/L,t1/2was1.7±0.3 h, andAUC0-twas (914.1±284.5) g·h/L. Calculated withAUC0-t, the bioavailability of two formulations was 105.0%.

Sensitive and rapid titrimetric and spectrophotometric methods for the determination of stavudine in pharmaceuticals using bromate-bromide and three dyes

Four sensitive and rapid methods for the determination of stavudine (STV) in bulk drug and in dosage forms were developed and optimized. In titrimetry, aqueous solution of STV was treated with a known excess of bromate-bromide in HCl medium followed by estimation of unreacted bromine by iodometric back titration. Spectrophotometric methods involve the addition of a measured excess of bromate-bromide in HCl medium and subsequent estimation of the residual bromine by reacting with a fixed amount of methyl orange, indigocarmine or thymol blue followed by measurement of absorbance at 520 nm (method A), 610 nm (method B) or 550 nm (method C). In all the methods, the amount of bromate reacted corresponds to the amount of STV. Calculations in titrimetry were based on a 1:0.666 (STV:KBrO3) stoichiometry and the method was found to be applicable over 3.5-10 mg range. A linear increase in absorbance with concentration of STV was observed in the spectrophotometric methods, and the Beer's law was obeyed over the concentration ranges 0.125-1.75, 1-10 and 1-9.0 microg mL-1 STV for method A, method B and method C, respectively. The methods when applied to the determination of STV in tablets and capsules were found to give satisfactory results.

Determination of stavudine in human plasma and urine by high-performance liquid chromatography using a reduced sample volume

Sensitive high-performance liquid chromatographic assays have been developed for the quantification of stavudine (2′,3′-didehydro-3′-deoxythymidine, d4T) in human plasma and urine. The methods are linear over the concentration ranges 0.025–25 and 2–150 μg/ml in plasma and urine, respectively. An aliquot of 200 μl of plasma was extracted with solid-phase extraction using Oasis ® cartridges, while urine samples were simply diluted 1/100 with HPLC water. The analytical column, mobile phase, instrumentation and chromatographic conditions are the same for both methods. The methods have been validated separately, and stability tests under various conditions have been performed. The detection limit is 12 ng/ml in plasma for a sample size of 200 μl. The bioanalytical assay has been used in a pharmacokinetic study of pregnant women and their newborns.

Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection

A sensitive high-performance liquid chromatographic assay has been developed to determine the levels of a new antiretroviral agent, stavudine (2′,3′-didehydro-3′-deoxythymidine, d4T), in human plasma. Didanosine (2′,3′-dideoxyinosine, ddI) was used as the internal standard. The very selective sample pretreatment involved solid-phase extraction using silica gel columns. Chromatography was carried out on a μBondapak phenyl column, using a mobile phase of 0.005 M phosphate buffer (pH 6.8)—methanol (90:10, v/v) and ultraviolet detection at 265 nm. The method has been validated, and stability tests under various conditions have been performed. The detection limit is 10 ng/ml (using 500-μl human plasma samples). The bioanalytical assay has been used in a single pharmacokinetic experiment in a rat to investigate the applicability of the method in vivo.